Abcam (LON:ABC) had its price target lowered by JPMorgan Chase & Co. from GBX 1,144 ($14.95) to GBX 1,134 ($14.82) in a report published on Monday morning, ThisIsMoney.Co.Uk reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.
ABC has been the topic of several other research reports. Berenberg Bank reiterated a buy rating and set a GBX 1,330 ($17.38) price target on shares of Abcam in a report on Monday, September 9th. Peel Hunt reiterated an add rating and set a GBX 1,300 ($16.99) price target (down previously from GBX 1,430 ($18.69)) on shares of Abcam in a report on Monday, September 9th.
Shares of ABC stock opened at GBX 1,172 ($15.31) on Monday. Abcam has a 12 month low of GBX 1,006 ($13.15) and a 12 month high of GBX 1,523 ($19.90). The business’s 50 day moving average is GBX 1,199.28 and its two-hundred day moving average is GBX 1,288.14. The company has a market cap of $2.42 billion and a PE ratio of 53.76.
In related news, insider Alan Thomas Hirzel acquired 4,250 shares of the stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average price of GBX 1,139 ($14.88) per share, for a total transaction of £48,407.50 ($63,252.97). Also, insider Gavin Wood acquired 2,500 shares of the stock in a transaction dated Friday, September 13th. The stock was bought at an average price of GBX 1,157 ($15.12) per share, for a total transaction of £28,925 ($37,795.64).
Abcam Company Profile
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
See Also: Commodities
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.